Compound News and Research

RSS

Ontario's doctors to stress the importance of health care professionals working together to the Standing Committee

At an appearance today before the Ontario Legislative Standing Committee on Social Policy, Ontario's doctors will stress the importance of health care professionals working together to enhance and strengthen the delivery of safe and quality care to patients.

30 Sep 2009

New treatment for Alzheimer's disease may be in the offing

Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.

30 Sep 2009

Research finds novel chemical that targets drug-resistant bacteria

Eric Brown, a professor and chair of the Department of Biochemistry and Biomedical Sciences, and a team of researchers from the Michael G. DeGroote Institute for Infectious Disease Research have identified a novel chemical compound that targets drug-resistant bacteria in a different way from existing antibiotics. The discovery could lead to new treatments to overcome antibiotic resistance in certain types of microorganisms.

29 Sep 2009

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for certain exclusively licensed intellectual property by the issuance to the University of Pennsylvania of U.S. patent number 7,590,517, “Methods, Systems, and Computer Program Products for Computational Design of Amphiphilic Polymers.”

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Researchers discover potential treatment for Friedreich's ataxia

Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials, which will be a welcome event for disease sufferers who currently have few treatment options.

25 Sep 2009

Huachansu may slow cancer progression

Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Walgreens ensures that all its pharmacies can provide Tamiflu

Less than a month after launching the largest flu prevention initiative in the company’s 108-year history, Walgreens is taking proactive measures to ensure its nearly 7,000 pharmacies can provide the suspension - or liquid - form of seasonal flu-fighting drug Tamiflu this season. Following Tamiflu manufacturer Roche’s notification that Tamiflu Oral Suspension is in short supply, Walgreens pharmacies in all 50 states are prepared to compound Tamiflu capsules into the liquid form to produce an Oral Suspension prescription. Tamiflu capsules remain in adequate supply.

24 Sep 2009

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

Adolor acquires exclusive worldwide rights to OpRA III

Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

Top 20 pharma companies seek out new partnering opportunities at BIO-Europe 2009

In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe.

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

23 Sep 2009

NIST collaborates with private industry to release a new reference material for beryllium

Researchers at the National Institute of Standards and Technology (NIST), in collaboration with private industry and other government agencies, have produced a new reference material for beryllium. Beryllium, an exotic rare-earth metal used as a hardener in high-performance alloys and ceramics, can cause berylliosis-a chronic, incurable and sometimes fatal illness.

23 Sep 2009

Bioscreen Instruments to be Labcyte's partner in India

Labcyte, the developer of acoustic liquid transfer, with systems in all top 10 pharmaceutical companies, today announced the selection of Bioscreen Instruments Pvt. Ltd. as its exclusive distributor in India.

23 Sep 2009

Drug trial for OSI-906 begins

TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

23 Sep 2009

Adjuvant formula to enhance existing vitamin products

Emergent Health Corp. (Other OTC: EMGE) -- Emergent expects to revolutionize the vitamin business. The company plans to introduce an adjuvant formula that enhances existing vitamin products currently on the market to assist in the production of normal cells.

23 Sep 2009

Health Robotics chooses Device Technologies Australia as its exclusive CytoCare partner for Oceania

Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Device Technologies Australia Pty Ltd. for its revolutionary CytoCare(TM) Robot. This strategic agreement enables Device Technologies Australia to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. Admixtures to complement its other market-leading Oncology and Surgery Robotic solutions.

22 Sep 2009

Compound News and Research

Ontario's doctors to stress the importance of health care professionals working together to the Standing Committee

New treatment for Alzheimer's disease may be in the offing

Research finds novel chemical that targets drug-resistant bacteria

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

European Commission grants conditional marketing authorization for Gilead's Cayston

Researchers discover potential treatment for Friedreich's ataxia

Huachansu may slow cancer progression

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Walgreens ensures that all its pharmacies can provide Tamiflu

ART's new generation Optix MX3 optical molecular imaging system unveiled

Adolor acquires exclusive worldwide rights to OpRA III

New drug test promises to yield quick and effective response for cancer therapy

Researchers make significant advances in the treatment of metastatic malignant melanoma

Top 20 pharma companies seek out new partnering opportunities at BIO-Europe 2009

Advancements in the treatment of metastatic malignant melanoma

NIST collaborates with private industry to release a new reference material for beryllium

Bioscreen Instruments to be Labcyte's partner in India

Drug trial for OSI-906 begins

Adjuvant formula to enhance existing vitamin products

Health Robotics chooses Device Technologies Australia as its exclusive CytoCare partner for Oceania

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News